XNAS
OTLK
Market cap139mUSD
Oct 08, Last price
0.56USD
1D
-4.41%
1Q
-64.08%
Jan 2017
-99.88%
IPO
-99.92%
Name
Outlook Therapeutics Inc
Chart & performance
P/E
—
P/S
97.14
EPS
—
Div yield, %
—
Shrs. gr., 5y
47.67%
Rev. gr., 5y
9.32%
Revenues
1m
Net income
-62m
L-17.17%
CFO
-52m
L-24.66%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to treat wet age-related macular degeneration and other serious retinal diseases. The company has forged strategic collaboration and licensing agreements with several partners, including IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. Incorporated in 2010, the firm was formerly known as Oncobiologics, Inc., changing its name to Outlook Therapeutics, Inc. in November 2018. Its corporate base is located in Iselin, New Jersey.
Key people
Robert Jahr
President, Chief Executive Officer, Director · since 2025
Lawrence Kenyon
Chief Financial Officer, Executive Vice President, Treasurer, Company Secretary, Director · since 2025
Gerd Auffarth
Independent Director · since 2020
Independent Director · since 2020
Yezan Haddadin
Independent Director · since 2018
Independent Director · since 2022
Independent Director · since 2015
Andong Huang
Independent Director · since 2020
Faisal Sukhtian
Independent Chairman of the Board · since 2025
Ralph Thurman
Lead Independent Director · since 2025
Legal address
C/O UNITED CORPORATE SERVICES, INC.
800 NORTH STATE STREET SUITE 304
DOVER, DE 19901
US
800 NORTH STATE STREET SUITE 304
DOVER, DE 19901
US
Headquarters
7 Clarke Drive
Cranbury, NJ 08512
US
Cranbury, NJ 08512
US
Previous name
Oncobiologics, Inc.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑09 | 2024‑09 | 2023‑09 | 2022‑09 | 2021‑09 | 2020‑09 | 2019‑09 | 2018‑09 | 2017‑09 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||